Complete Case

(HealthDay News) — Eli Lilly and Co. is seeking U.S. approval for emergency use of an experimental antibody therapy for COVID-19.

The request to the U.S. Food and Drug Administration is based on partial clinical trial findings suggesting the drug reduced symptoms, the amount of virus, hospitalizations, and emergency department visits for patients with mild or moderate COVID-19, the Associated Press reported.

The results were released Wednesday in a news release, and they have not been published or reviewed by independent researchers.

The FDA granted emergency approval for the antiviral drug remdesivir, but it is not clear if there is enough evidence for Lilly’s antibody therapy to be approved, the AP reported.

AP News Article

Search our drug information database which contains an extensive list of psychiatric drugs.

Our drug database contains over 4,000 concise product monographs (OTC & Rx) and is organized by brand name, generic name, and disease state. Each monograph includes indication, dose, contraindications, precautions, interactions, adverse reactions, manufacturer, and how supplied information. We even offer you the ability to compare drugs side-by-side, and search for information on pharmaceutical companies.

Powered by Monthly Prescribing Reference